

FROM: ADE & COMPANY

(FRI) OCT 22 2004 16:13/ST. 16:13/NO. 631-0677779 P 1

RECEIVED  
CENTRAL FAX CENTER

**ADE & COMPANY  
PATENT AND TRADEMARK AGENTS**

Adrian D. Battison, B.Sc.  
(F.C.I.P.A. (London))

Michael R. Williams.  
Ryan W. Dupuis

Consultants  
Ronald S. Ade  
Steven Z. Raber

Suite 1700 Winnipeg Square  
360 Main Street  
Winnipeg, Manitoba  
Canada R3C 3Z3

OCT 22 2004

84894-602

**FACSIMILE COVER LETTER**

**PLEASE DELIVER THE FOLLOWING PAGES TO:**

**NAME: Commissioner of Patents – Russell S., Travers**

**FROM: Ade & Company – Michael R. Williams**

**TOTAL NUMBER OF PAGES 11 INCLUDING THIS COVER LETTER.**

**DATE: October 22, 2004**

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENTS NAMED ABOVE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL.

---

**RE: United States Patent Application no: 09/878,918  
Gordon W. Glazner  
Therapeutic Uses for IP3 Receptor-Mediated Calcium Channel  
Modulators  
EXAMINER –Russell S. Travers GROUP 1617**

---

**Response/amendment to Notice of Action dated June 25, 2004 and a  
request for a 1 MONTH extension of time in duplicate.**

**IF ALL PAGES ARE NOT RECEIVED OR ANY ARE NOT LEGIBLE. PLEASE  
CALL AS SOON AS POSSIBLE.**

**TELEPHONE (204)-947-1429**

**FACSIMILE (204)-942-5723**

**OPERATOR: Doris Jones**

**RECEIVED<sup>1</sup>**  
**CENTRAL FAX CENTER**

**OCT 22 2004**

**EXAMINER**            **Russell S. Travers**  
**GROUP**              **1617**  
**APPLICANT**        **Gordon W. Glazner**  
**SERIAL NO:**        **09/576,130**  
**FILED**              **June 13, 2001**  
**FOR**                **THERAPEUTIC USES FOR IP3 RECEPTOR-MEDIATED**  
                         **CALCIUM CHANNEL MODULATORS**

**Commissioner of Patents**  
**Washington, D.C., 20231**  
**U.S.A.**

**Dear Sir:**

**Responsive to the Notice of Action dated June 25, 2004,**